	US 11,814,442 B2
	Immunoglobulin compositions and process for obtaining the same
Yuval Sagiv, Gedera (IL); and Shahar Nisemblat, Kfar Saba (IL)
Assigned to KAMADA LTD., Rehovot (IL)
Appl. No. 16/621,374
Filed by KAMADA LTD., Rechovot (IL)
PCT Filed Jun. 12, 2018, PCT No. PCT/IL2018/050642 § 371(c)(1), (2) Date Dec. 11, 2019, PCT Pub. No. WO2018/229760, PCT Pub. Date Dec. 20, 2018.
Claims priority of provisional application 62/518,005, filed on Jun. 12, 2017.
Prior Publication US 2020/0157242 A1, May 21, 2020
Int. Cl. C07K 16/34 (2006.01); A61P 37/04 (2006.01); C07K 16/06 (2006.01)

CPC C07K 16/34 (2013.01) [A61P 37/04 (2018.01); C07K 16/065 (2013.01)]

12 Claims

1. A method of activating and removing a thrombogenic agent from an immunoglobulin containing solution, comprising subjecting human plasma or fractions thereof to gel filtration column chromatography, and an euglobulin precipitation step;

wherein the euglobulin precipitation incubation time is about 8-72 hrs;

wherein the immunoglobulin containing solution is kept at a temperature in the range of about 24° C. to about 25° C.; and

wherein the method further comprises an anion exchange column chromatography enrichment step for enriching the immunoglobulin containing solution; and

wherein the method results in an isolated or purified immunoglobulin composition comprising factor XI activity equal or below 8 mIU/ml.